Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Current Investments (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Cash & Current Investments for 3 consecutive years, with $209.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 65.3% to $209.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $209.5 million through Dec 2025, up 65.3% year-over-year, with the annual reading at $209.5 million for FY2025, 65.3% up from the prior year.
  • Cash & Current Investments hit $209.5 million in Q4 2025 for Compass Therapeutics, down from $220.5 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $220.5 million in Q3 2025 to a low of $100.9 million in Q2 2025.
  • Historically, Cash & Current Investments has averaged $155.8 million across 3 years, with a median of $154.5 million in 2023.
  • Biggest YoY gain for Cash & Current Investments was 65.3% in 2025; the steepest drop was 30.96% in 2025.
  • Year by year, Cash & Current Investments stood at $152.5 million in 2023, then decreased by 16.88% to $126.7 million in 2024, then skyrocketed by 65.3% to $209.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for CMPX at $209.5 million in Q4 2025, $220.5 million in Q3 2025, and $100.9 million in Q2 2025.